The Role of Bridging Therapy in Hepatocellular Carcinoma

Table 1

Patient demographics.

Patient demographics
Age	56	(36–72)
Sex
Male	78	81.30%
Female	18	18.70%
Incidental	31	32.30%
ALD	40	41.70%
HCV	48	50%
BT	19	29.20%
Size of greater lesion (mean)	2.3	(0.7–7.6 cm)
Single	51	54.40%
Vascular invasion	22	22.90%

Alcoholic liver disease (ALD);  hepatitis C cirrhosis (HCV);  bridging therapy (BT).